NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free VVOS Stock Alerts $4.83 +0.18 (+3.87%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.31▼$4.8550-Day Range$4.26▼$7.5552-Week Range$2.73▼$48.79Volume113,892 shsAverage Volume117,388 shsMarket Capitalization$6.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vivos Therapeutics alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Vivos Therapeutics Stock (NASDAQ:VVOS)Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.Read More VVOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VVOS Stock News HeadlinesMarch 29, 2024 | marketwatch.comVivos Therapeutics Shares Fall After Wider-Than-Expected 4Q LossMarch 28, 2024 | globenewswire.comVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateMarch 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 28, 2024 | globenewswire.comVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesFebruary 18, 2024 | investing.comVivos Therapeutics secures $4 million through warrant exerciseFebruary 15, 2024 | finance.yahoo.comVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.February 15, 2024 | proactiveinvestors.comVivos Therapeutics sees gross proceeds of $4M from exercise of warrantFebruary 12, 2024 | finance.yahoo.comVivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market DisruptionsFebruary 6, 2024 | finanznachrichten.deVivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesFebruary 6, 2024 | finance.yahoo.comVivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesJanuary 8, 2024 | finance.yahoo.comVivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSADecember 11, 2023 | proactiveinvestors.comVivos Therapeutics announces women-led airway health eventDecember 11, 2023 | finance.yahoo.comVivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”December 1, 2023 | proactiveinvestors.comVivos Therapeutics severe sleep apnea treatment’s a ‘breakthrough’, says CEONovember 30, 2023 | benzinga.comThinking about buying stock in Minim Inc, Walmart, Farfetch Ltd, Qualcomm, or Vivos Therapeutics Inc?November 30, 2023 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Down 35% Today?November 30, 2023 | msn.comPhilips shares slump as FDA says sleep product may overheatNovember 29, 2023 | proactiveinvestors.comVivos Therapeutics: Who is the medical device company creating frenzy in the markets?November 29, 2023 | proactiveinvestors.comVivos Therapeutics receives first ever FDA 510(k) clearance...Vivos Therapeutics receives first ever FDA 510(k) clearance for...November 29, 2023 | msn.comVivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearanceNovember 29, 2023 | finance.yahoo.comUPDATE 2-US FDA clears Vivos Therapeutics' oral device for sleep apneaNovember 29, 2023 | finance.yahoo.comVivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apneaNovember 29, 2023 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Up 290% Today?November 29, 2023 | reuters.comUS FDA clears Vivos Therapeutics' oral device treatment for sleep apneaSee More Headlines Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/29/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:VVOS CUSIPN/A CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees154Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,840,000.00 Net Margins-106.28% Pretax Margin-106.27% Return on Equity-508.27% Return on Assets-129.15% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual Sales$16.02 million Price / Sales0.40 Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / Book1.01Miscellaneous Outstanding Shares1,330,000Free Float1,204,000Market Cap$6.42 million OptionableOptionable Beta8.04 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. R. Kirk Huntsman (Age 66)Co-Founder, Chairman of the Board & CEO Comp: $454.05kMr. Bradford K. Amman (Age 62)CFO, Treasurer & Secretary Comp: $297.23kMr. Todd HuntsmanCo-Founder & Senior VP of Product and TechnologyMs. RaeAnn ByrnesCo-Founder and Senior VP of Events & Clinical Advisory ServicesMs. Susan McCulloughCo-Founder & Executive VP of OperationsMs. Julie GannonSenior VP of Strategic Sales & Marketing and Investor Relations OfficerMr. Nicholas M. DeGennaroSenior Vice President of Medical Integration DivisionMs. Ruth HembreeSenior Vice President of Practice ServicesMs. Stephanie HuebnerSenior Vice President of Dental Service IntegrationMr. John BallardSenior Vice President of TechnologyMore ExecutivesKey CompetitorsAcutus MedicalNASDAQ:AFIBTitan MedicalNASDAQ:TMDIFSharps TechnologyNASDAQ:STSSGlucoTrackNASDAQ:GCTKMinerva SurgicalNASDAQ:UTRSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 604,436 shares on 3/11/2024Ownership: 0.795%Vanguard Group Inc.Sold 604,436 shares on 2/15/2024Ownership: 0.794%Armistice Capital LLCBought 57,000 shares on 2/13/2024Ownership: 4.286%Strategic Wealth Investment Group LLCSold 3,090,916 shares on 1/16/2024Ownership: 9.683%Ronald Kirk HuntsmanBought 560 shares on 6/20/2023Total: $7,420.00 ($13.25/share)View All Insider TransactionsView All Institutional Transactions VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed in 2024? Vivos Therapeutics' stock was trading at $12.44 at the beginning of 2024. Since then, VVOS stock has decreased by 61.2% and is now trading at $4.83. View the best growth stocks for 2024 here. When is Vivos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our VVOS earnings forecast. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its earnings results on Monday, November, 15th. The company reported ($6.50) EPS for the quarter, missing the consensus estimate of ($4.00) by $2.50. The company had revenue of $4.55 million for the quarter, compared to the consensus estimate of $4.50 million. Vivos Therapeutics had a negative net margin of 106.28% and a negative trailing twelve-month return on equity of 508.27%. When did Vivos Therapeutics' stock split? Shares of Vivos Therapeutics reverse split before market open on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. Who are Vivos Therapeutics' major shareholders? Vivos Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Strategic Wealth Investment Group LLC (9.68%), Armistice Capital LLC (4.29%), Vanguard Group Inc. (0.80%), Vanguard Group Inc. (0.79%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford K Amman and Ronald Kirk Huntsman. View institutional ownership trends. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VVOS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy SykesMost important medical advance in 100 yearsThe Oxford ClubThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.